Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lizhu
Guangdong, Chinaen.joincare.com ↗
- Ownership
- Private
- Employees
- ~8000
- Development stage
- Other
01
Overview
Lizhu is a top Chinese pharmaceutical group with commercialized portfolios in small molecule, biologic, and recombinant protein drugs, including innovative and generic agents in digestive, cardiovascular, reproductive, and neurological areas.[1][5][9] Notable recent clinical achievements include successful product approvals in digestive therapeutics and ongoing expansion into new indications such as venous thromboembolism prevention.[3][7]
- Therapeutic areas
- EndocrinologyGastroenterologyCardiovascularOtherOncologyNeurology
- Modalities
- Small moleculeSynthetic peptideMonoclonal antibodyBiologicRecombinant protein
- Industry
- Biotech
02
Partnerships
Nanjing Vcare PharmaTechShanghai Huahuituo Pharmaceutical Technology
Beyond the preview
Go deeper on Lizhu.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lizhu.